公开(公告)号：US20230381178A1

公开(公告)日：2023-11-30

申请号：US18032450

申请日：2021-10-29

申请人： Resverlogix Corp.

发明人： Kenneth Eugene LEBIODA ,  Christopher Ross Armstrong HALLIDAY ,  Aziz Naeem KHAN

IPC分类号： A61K31/517 ,  A61K31/7048 ,  A61K31/7042 ,  A61K31/70 ,  A61P13/12

CPC分类号： A61K31/517 ,  A61K31/7048 ,  A61K31/7042 ,  A61K31/70 ,  A61P13/12

摘要： Described herein are methods for treating and/or preventing a kidney disease or an associated disorder as measured by an increase in estimated glomerular filtration rate (eGFR) by administering to a subject in need thereof, a combination of a sodium-glucose transport protein 2 (SGLT2) inhibitor and a compound of Formula I or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein the variables of Formula I are as defined herein.

公开(公告)号：US11826378B2

公开(公告)日：2023-11-28

申请号：US17176285

申请日：2021-02-16

申请人： Boehringer Ingelheim Vetmedica GmbH

发明人： Carla Kroh ,  Ingo Ulrich Lang ,  Horst Rose ,  Franziska Roessner ,  Saskia Kley

IPC分类号： A61K31/7034 ,  A61K47/54 ,  A61P9/04 ,  A61K31/138 ,  A61K31/341 ,  A61K31/401 ,  A61K31/4184 ,  A61K31/4422 ,  A61K31/501 ,  A61K31/554 ,  A61K31/585 ,  A61K31/616 ,  A61K31/7042 ,  A61K31/7048 ,  A61K31/7056 ,  A61K31/727

CPC分类号： A61K31/7034 ,  A61K31/138 ,  A61K31/341 ,  A61K31/401 ,  A61K31/4184 ,  A61K31/4422 ,  A61K31/501 ,  A61K31/554 ,  A61K31/585 ,  A61K31/616 ,  A61K31/7042 ,  A61K31/7048 ,  A61K31/7056 ,  A61K31/727 ,  A61K47/545 ,  A61P9/04

摘要： The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof for the prophylaxis and/or treatment of one or more cardiac diseases in feline animals.

公开(公告)号：US20230372375A1

公开(公告)日：2023-11-23

申请号：US18029062

申请日：2020-09-30

申请人： Beijing Creatron Institute of Pharmaceutical Research Co. Ltd.

发明人： Huijuan JIA ,  Wei HOU ,  Yanxin WANG ,  Yan LI ,  Xiaohui REN ,  Tiange JIA

IPC分类号： A61K31/7042 ,  A61K31/198

CPC分类号： A61K31/7042 ,  A61K31/198

摘要： Provided are an SGLT-2 inhibitor-sarcosine cocrystal, a preparation method therefor and use thereof. Using sarcosine as a ligand, said cocrystal has higher safety and lower costs; a drug cocrystal has higher stability, and during the production process or storage process of a formulation composition, the crystal form is not easily changed; said cocrystal does not melt when heated, does not stick, aggregate or generate static electricity, and has better mixing uniformity. Said cocrystal has uniform distribution in a prepared pharmaceutical composition, causing that the pharmaceutical composition has better in-vivo release, absorption and efficacy, and has small difference between batches; and the pharmaceutical composition has high stability, and is more conducive to storage and transportation. The present invention has a simple preparation process, has high reproducibility, has short crystallization time, has low process condition requirements, and has higher economic benefits; the present invention does not use an unsafe solvent during the preparation process; and a crude product or intermediate of the SGLT-2 inhibitor can be simultaneously purified.

公开(公告)号：US11813244B2

公开(公告)日：2023-11-14

申请号：US17143689

申请日：2021-01-07

申请人： NIIGATA UNIVERSITY ,  MITSUBISHI TANABE PHARMA CORPORATION

发明人： Tohru Minamino

IPC分类号： A61K31/351 ,  A61K31/7042 ,  A61K31/381 ,  A61K45/00 ,  A61P43/00 ,  A61P7/02

CPC分类号： A61K31/381 ,  A61K45/00 ,  A61P7/02 ,  A61P43/00

摘要： The present invention provides an agent or pharmaceutical composition for eliminating senescent cells, comprising an SGLT2 inhibitor.

公开(公告)号：US11759474B2

公开(公告)日：2023-09-19

申请号：US17104414

申请日：2020-11-25

申请人： Boehringer Ingelheim Vetmedica GmbH

发明人： Dania Birte Reiche

IPC分类号： A61K31/7048 ,  A23K20/24 ,  A23K20/121 ,  A61P15/14 ,  A61K31/351 ,  A61K31/381 ,  A61K31/7056 ,  A61K31/382 ,  A61K31/7028 ,  A61K31/7034 ,  A61K31/7042

CPC分类号： A61K31/7048 ,  A23K20/121 ,  A23K20/24 ,  A61K31/351 ,  A61K31/381 ,  A61K31/382 ,  A61K31/7028 ,  A61K31/7034 ,  A61K31/7042 ,  A61K31/7056 ,  A61P15/14

摘要： The present invention is directed to the use of at least one SGLT-2 inhibitor in a non-human mammal, preferably ruminant, preferably for drying-off of a non-human mammal, preferably ruminant, as well as corresponding methods, such as improving and/or facilitating the drying-off of a non-human mammal, preferably ruminant, comprising administering to such non-human mammal, preferably ruminant, at least one SGLT-2 inhibitor.

公开(公告)号：US20230270718A1

公开(公告)日：2023-08-31

申请号：US17995798

申请日：2021-04-12

申请人： Chinook Therapeutics, Inc. ,  AbbVie Inc.

发明人： Joel Z. Melnick ,  Michael G. Miller ,  Tingting YI ,  Hiddo Lambers Heerspink ,  Andrew James King ,  Sarah B. Noonberg

IPC分类号： A61K31/4025 ,  A61K45/06 ,  A61K31/7042 ,  A61K31/7048 ,  A61K31/70 ,  A61K31/382 ,  A61P3/10 ,  A61P13/12

CPC分类号： A61K31/4025 ,  A61K45/06 ,  A61K31/7042 ,  A61K31/7048 ,  A61K31/70 ,  A61K31/382 ,  A61P3/10 ,  A61P13/12

摘要： Provided herein are methods of treating diabetic kidney disease comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, and a SGLT-2 inhibitor to a subject in need thereof.

公开(公告)号：US20230190742A1

公开(公告)日：2023-06-22

申请号：US17960669

申请日：2022-10-05

申请人： Mirum Pharmaceuticals, inc.

发明人： Thomas JAECKLIN ,  Alejandro DORENBAUM

IPC分类号： A61K31/4995 ,  A61P1/16 ,  A61P17/04 ,  A61K31/554 ,  A61K31/7042 ,  G01N33/68

CPC分类号： A61K31/4995 ,  A61K31/554 ,  A61K31/7042 ,  A61P1/16 ,  A61P17/04 ,  G01N33/6893 ,  G01N2800/085

摘要： Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 µg/kg/day.

公开(公告)号：US20230094463A1

公开(公告)日：2023-03-30

申请号：US17777573

申请日：2020-12-03

申请人： TrueBinding, Inc.

发明人： Dongxu Sun ,  Jing Zhang ,  Maja Bonacorsi ,  Yinan Wu ,  Yadong Yu ,  Catherine A. Gordon ,  Tsung-Huang Tsai ,  Ksenya Shchors ,  Samuel A.F. Williams

IPC分类号： C07K16/28 ,  A61K38/28 ,  A61K31/155 ,  A61K31/4439 ,  A61K38/26 ,  A61K31/4985 ,  A61K31/522 ,  A61K31/513 ,  A61K31/351 ,  A61K31/7042 ,  A61K31/7048 ,  A61K31/196 ,  A61K31/573 ,  A61K31/52 ,  A61K31/519 ,  A61K31/439 ,  A61K39/395 ,  A61P3/10 ,  A61P1/12 ,  G01N33/68

摘要： Disclosed herein are methods and compositions for disrupting an interaction between Galectin-3 and insulin receptor or integrins. Further disclosed herein are methods and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of diabetes mellitus, inflammatory bowel syndrome, non-alcoholic fatty liver disease, and nonalcoholic steatohepatitis.

公开(公告)号：US11576894B2

公开(公告)日：2023-02-14

申请号：US15413480

申请日：2017-01-24

申请人： Janssen Pharmaceutica N.V.

发明人： Yin Liang ,  John Ryan ,  Abraham B. Woldu ,  Lisa Wu

IPC分类号： A61K31/7034 ,  A61K31/7042 ,  A61K31/155 ,  A61K31/381 ,  A61K47/38 ,  A61K31/4436

摘要： The present invention is directed to co-therapy and methods for the treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X. The present invention is further directed to pharmaceutical compositions for the co-therapy and methods described herein.

公开(公告)号：US11564903B2

公开(公告)日：2023-01-31

申请号：US17063491

申请日：2020-10-05

申请人： Microbion Corporation

发明人： Brett Hugh James Baker ,  Philip Domenico

IPC分类号： A61K31/29 ,  A61K9/00 ,  A61K31/095 ,  A61K33/245 ,  A61K9/14 ,  A61K31/165 ,  A61K31/426 ,  A61K31/496 ,  A61K31/65 ,  A61K31/7036 ,  A61K31/704 ,  A61K31/7042 ,  A61K38/14 ,  A61K45/06

摘要： Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.